Tevogen Bio Holdings Inc.
TVGN
$7.00
-$2.54-26.63%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -49.79% | -32.21% | 16.63% | 30.13% | 79.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.42% | -51.20% | -33.15% | -26.39% | -4.53% |
| Operating Income | 38.42% | 51.20% | 33.15% | 26.39% | 4.53% |
| Income Before Tax | 39.61% | -91.41% | -292.20% | -425.62% | -91.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.61% | -91.41% | -292.20% | -425.62% | -91.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.61% | -91.41% | -292.20% | -425.62% | -91.58% |
| EBIT | 38.42% | 51.20% | 33.15% | 26.39% | 4.53% |
| EBITDA | 38.66% | 51.41% | 33.28% | 26.60% | 4.54% |
| EPS Basic | 38.58% | -101.00% | -48.08% | -53.74% | 20.94% |
| Normalized Basic EPS | 45.66% | 58.01% | 48.02% | 44.99% | 29.15% |
| EPS Diluted | 38.74% | 59.23% | 55.62% | 54.41% | 63.48% |
| Normalized Diluted EPS | 45.66% | 57.19% | 47.03% | 43.90% | 27.57% |
| Average Basic Shares Outstanding | 10.96% | 13.39% | 33.31% | 42.71% | 47.34% |
| Average Diluted Shares Outstanding | 10.96% | 12.39% | 31.93% | 41.08% | 45.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |